|Year : 2022 | Volume
| Issue : 3 | Page : 200-207
Phenotypic detection of ESBL-producing Enterobacteriaceae using combined disk diffusion, ESBL HiCrome agar, and E-test: A comparative study
Swetalina Dash1, Susmita Kumari Sahu1, Bimoch Projna Paty2
1 Department of Microbiology, MKCG Medical College, Berhampur, Odisha, India
2 Department of Microbiology, SCB Medical College, Cuttack, Odisha, India
|Date of Submission||28-Jul-2021|
|Date of Decision||05-Oct-2021|
|Date of Acceptance||03-Dec-2021|
|Date of Web Publication||26-Dec-2022|
Dr. Swetalina Dash
Department of Microbiology, MKCG Medical College, Berhampur, Odisha
Source of Support: None, Conflict of Interest: None
Background: Extended-spectrum beta-lactamases (ESBLs) are in a rising trend in recent years, creating confusion for physicians to choose appropriate antimicrobials for treatment.
Aim: The aim of the study is to detect ESBL-producing Enterobacteriaceae by using rapid detection tests such as combined disk diffusion, ESBL E-test strips (based on cefotaxime and cefotaxime+clavulanate), and ESBL HiCrome agar and compare the efficacy of these tests.
Materials and Methods: Samples were processed using conventional methods. Bacterial antibiotic susceptibility testing was done on Mueller-Hinton agar according to the Clinical and Laboratory Standards Institute guidelines. All Enterobacteriaceae isolates were subjected to ESBL HiCrome agar, combined disk diffusion, and E-test.
Results: Out of 5299 samples, 2097 (39.57%) were culture-positive, and 200 (9.5%) Enterobacteriaceae isolates were obtained. The majority of the isolates were Escherichia coli (67.5%), followed by Klebsiella pneumoniae (25%), Proteus mirabilis (3.5%), Proteus vulgaris (2%), and Citrobacter freundii (2%). 29.5% of all Enterobacteriaceae isolates were found to be ESBL producers by combined disk diffusion, ESBL HiCrome agar, and E-test methods, which showed 100% concordance.
Conclusion: It is important to identify ESBL-producing Enterobacteriaceae from clinical samples for the judicious use of antibiotics. For early detection of ESBL-producing Enterobacteriaceae isolates, combined disk diffusion, ESBL HiCrome agar, and E tests were found to be equally effective in detecting ESBL production.
Keywords: ESBL, E-test, HiCrome agar
|How to cite this article:|
Dash S, Sahu SK, Paty BP. Phenotypic detection of ESBL-producing Enterobacteriaceae using combined disk diffusion, ESBL HiCrome agar, and E-test: A comparative study. J NTR Univ Health Sci 2022;11:200-7
|How to cite this URL:|
Dash S, Sahu SK, Paty BP. Phenotypic detection of ESBL-producing Enterobacteriaceae using combined disk diffusion, ESBL HiCrome agar, and E-test: A comparative study. J NTR Univ Health Sci [serial online] 2022 [cited 2023 Feb 7];11:200-7. Available from: https://www.jdrntruhs.org/text.asp?2022/11/3/200/365006
| Introduction|| |
Extended-spectrum beta-lactamases (ESBLs) are plasmid-mediated beta-lactamases capable of hydrolyzing and inactivating ESBLs with an oxyimino side chain such as cephalosporins (cefotaxime, ceftriaxone, and ceftazidime) and oxyimino-monobactam (aztreonam). They have no detectable activity against cephamycins and carbapenems. The Clinical and Laboratory Standards Institute (CLSI) issued national guidelines for the laboratory detection of Escherichia More Details. coli, Proteus mirabilis, and Klebsiella spp. with ESBLs. Previous studies in India have reported that the incidence of ESBLs ranges from 6 to 87%.,,,, Increase in infections due to ESBL-producing Enterobacteriaceae is now on the rise. ESBL-producing Enterobacteriaceae are important members of antibiotic-resistant bacteria causing hospital and community-acquired infections. Gram-negative bacteria of the family Enterobacteriaceae cause mostly urinary tract infections, bloodstream infections, intra-abdominal infections, and hospital-associated pneumonia. Infections caused by ESBL-producing organisms are associated with higher morbidity and mortality. To date, there are >350 natural ESBL variants known, and they have been classified into 9 structural and evolutionary families based upon the amino acid sequences such as TEM, SHV, CTX-M, PER, VEB, GES, BES, TLA, and OXA. Nowadays, treating ESBL-producing strains is a major challenge for physicians. Rampant use of β-lactam antibiotics such as penicillin, cephalosporins, monobactam, and carbapenems led to the emergence of their resistance. Some authors suggested the use of β-lactam/β-lactam inhibitors in combination as empirical therapy for ESBL-producing Gram-negative bacteria. ESBLs may not always be detected in routine susceptibility tests, and selection of antibiotic or antibiotic combination becomes difficult, and because no data regarding the prevalence of ESBLs is available in our area, the aim of this study is to detect ESBL-producing Enterobacteriaceae by using rapid detection tests such as combined disk diffusion, ESBL E-test strips (based on cefotaxime and cefotaxime+clavulanate) and ESBL HiCrome agar and compare the efficacy of these tests.
| Materials and Methods|| |
The present study was a prospective, observational, and hospital-based study which was conducted over a period of two years from October 2018 to September 2020 in the Department of Microbiology, M.K.C.G. Medical College and Hospital, Berhampur, India, in collaboration with different clinical departments of the same hospital.
The study was carried out on 5299 patients attending outpatient or admitted to various departments such as the Department of Surgery, Obstetrics and Gynaecology, Medicine, Paediatrics, Orthopaedics, and I.C.U. of M.K.C.G Medical College and Hospital, Berhampur, India.
Clinical samples, that is, urine, pus/wound swabs, blood, and body fluids were collected from patients and transferred to the laboratory without delay for further processing.
- Escherichia. coli isolated from the stool of adult patients where it is a commensal.
- All other bacteria isolated other than Enterobacteriaceae.
Patients' demographic details, brief clinical history, details of diagnosis (as made by the consultant-in-charge of the concerned department), the date of admission to the hospital, duration of stay in the hospital, and antibiotic treatment were taken.
Informed consent was taken from all the patients concerned, and institutional ethical committee clearance was obtained.
All of the samples collected were cultured aerobically on pre-dried solid media, that is, blood and MacConkey agar. They were properly labeled with the patient ID. The cultured plates were incubated at 37°C for 48 hours and examined for growth.
Identification of the organism
Organisms were identified by colony morphology, Gram staining, biochemical reactions, and motility tests after inoculating them on routine media used in our microbiology laboratory. An antimicrobial susceptibility test was performed for all Enterobacteriaceae isolates with positive cultures according to Kirby Bauer's disk diffusion method. All Enterobacteriaceae isolates were subjected to the combined disk test, ESBL HiCrome agar, and E-test for the detection of ESBL producers.
Combined disk test
Disks containing 30 μg of cefotaxime or ceftazidime and disks containing a combination of the two drugs plus 10 μg of clavulanic acid (HiMedia, Mumbai, India) were placed independently, 30 mm apart, on a lawn culture of 0.5 McFarland opacity of the test isolate on a Mueller-Hinton agar plate and incubated for 18–24 hours at 35°C. Isolates were considered ESBL-positive if the inhibition zone measured around one of the combination disks after overnight incubation was at least 5 mm larger than that of the corresponding cephalosporin disk [Figure 1]. As per CLSI 2019, Escherichia coli 22 strains and Klebsiella pneumoniae ATCC 700603 strains were taken as the appropriate negative and positive controls, respectively.
|Figure 1: Combined disk diffusion test showing a positive result for ESBL production|
Click here to view
The Enterobacteriaceae isolates which were positive in the confirmatory combined disk diffusion test were subjected to the E-test for the measurement of minimum inhibitory concentration (MIC) of ceftazidime and ceftazidime + clavulanic acid and cefotaxime and cefotaxime + clavulanic acid. A MIC-determining paper strip (HiMedia E strip) was coated on two sides, one side with a single drug (cefotaxime or ceftazidime) and on the other side with a combination of these drugs with clavulanic acid in a concentration gradient manner, capable of showing MICs in the range of 0.25–128 μg/ml (ceftazidime [CAZ]) and 0.25/4–128/4 μg/ml (ceftazidime + clavulanic acid [CAZ+]) and other MICs in the range of 0.25–64 μg/ml (cefotaxime [CTX]) and 0.25/4–64/4 μg/ml (cefotaxime + clavulanic acid [CTX+]) on testing against the test organism.
- Muller-Hinton agar plates were prepared.
- A sterile non-toxic cotton swab on a wooden applicator was dipped into the standardized inoculum and rotated firmly against the upper inside wall of the tube to express excess fluid.
- The entire agar surface of the plate was streaked with the swab three times, turning the plates at a 60° angle between each streaking.
- The Ezy MIC strip was removed from the container from cold and kept at room temperature for 15 minutes before opening.
- One applicator was removed from the self-sealing bag stored at room temperature.
- The applicator was held in the middle and gently pressed on its broader sticky side on the center of the Ezy MIC™ strip.
- The applicator was lifted along with the attached Ezy MIC strip.
- The strip was placed at the desired position on the agar plate swabbed with the test culture.
- The plates were transferred into the incubator under appropriate conditions.
The isolate showing MIC reduction of ceftazidime or cefotaxime by 3 two-fold dilutions in the presence of clavulanic acid is considered as an ESBL producer [Figure 2] and [Figure 3].
|Figure 2: Confirmatory E-test using CTX/CTX + E strips showing >3 2-folds decrease in the MIC of cefotaxime after adding clavulanate|
Click here to view
|Figure 3: Confirmatory E-test using CAZ/CAZ + E strips showing >3 2-folds decrease in MIC of ceftazidime after adding clavulanate|
Click here to view
ESBL HiCrome agar
The test organisms were inoculated onto CHROMagar using the spread-plate technique of direct streaking and then incubated at 37°C for 18–24 hours. Colonies of ESBL producers develop species-specific colors.
The colony morphology on ESBL HiCrome agar is as follows [Figure 4] and [Figure 5]
|Figure 4: HiCrome agar showing ESBL-producing blue-colored Klebsiella colonies and pink-colored Escherichia coli colonies|
Click here to view
|Figure 5: HiCrome agar showing ESBL-producing blue-colored Klebsiella colonies and pink-colored Escherichia coli colonies and yellowish-brown colonies of Proteus spp|
Click here to view
ESBL-producing E coli: pink to reddish colonies.
ESBL-producing Klebsiella spp.: metallic blue colonies.
ESBL-producing Proteus spp.: brown halo colonies.
ESBL non-producers: inhibited.
| Results|| |
Out of 5299 samples, 2097 (39.57%) were cultured positive and 200 (9.5%) Enterobacteriaceae isolates were obtained. A majority of the isolates were Escherichia coli (67.5%), followed by Klebsiella pneumoniae (25%), Proteus mirabilis (3.5%), Proteus vulgaris (2%), and Citrobacter freundii (2%).
The antibiotic sensitivity pattern of the Enterobacteriaceae showed that a maximum number of Enterobacteriaceae isolates were resistant to cefotaxime (82%), followed by levofloxacin (63.5%) and amoxiclav (57.5%). Most of the isolates were sensitive to piperacillin tazobactam (71.5%) and imipenem (50%) [Table 1].
|Table 1: Antibiotic resistance among enterobacteriaceae isolates (n=200)|
Click here to view
Out of 200 Enterobacteriaceae isolates, 59 (29.5%) were found to be ESBL-positive by the combined disk diffusion method [Figure 1]. The majority of ESBL producers were found to be Escherichia coli [42 (71.1%)], followed by Klebsiella pneumoniae [13 (22%)] and Proteus mirabilis [4 (6.8%)].
All 59 ESBL isolates were subjected to the E-test [Figure 2] and [Figure 3] and HiCrome agar [Figure 4] and [Figure 5] test, and it was found that all 59 isolates showed a positive result in both tests (100%) [Table 2].
|Table 2: Comparison of different phenotypic methods for detection of ESBL|
Click here to view
| Discussion|| |
The frequency of use of antibiotics and even the dosages and period of administration vary greatly from country to country, region to region, and to some degree even in a locality. This has led to large differentials in the emergence of resistant patterns. The detection of ESBL production is of paramount importance both in hospital and community isolates. Infection-control practitioners and clinicians need the clinical laboratory to rapidly identify and characterize different types of resistant bacteria. This in turn is required to minimize the spread of these bacteria and help select appropriate antibiotics. Acquisition of efficient mobile elements results in acceleration of the transfer of various antibiotic resistance genes. Probably, a ''super bug'', resistant to relatively all licensed antibiotics, may arise in the future.
In our present study, out of 5299 samples, 2097 (39.57%) were cultured positive. Out of the 2097 cultured positive isolates, 200 (9.5%) isolates were Enterobacteriaceae, which was lower in comparison to Lohani et al.'s study, where, from 550 clinical samples, 343 (62.36%) were culture-positive and 157 (28.54%) Enterobacteriaceae isolates were obtained.
In our study, Escherichia coli (67.5%) was the major isolate, followed by Klebsiella pneumoniae (25%), Proteus mirabilis (3.5%), Proteus vulgaris (2%), and Citrobacter freundii (2%), similar to those reported in other studies.,,,,,, However, in Chandel et al.'s study, Klebsiella pneumoniae was the predominant isolate, and in Giriyapur et al.'s study, Klebsiella oxytoca was the major isolate.
In this study, the maximum number of Enterobacteriaceae isolated were from urine (55%) followed by pus (30%), blood (8.5%), sputum (5.5%), and throat swab (1%), similar to those in Emmanuel et al.'s and Moglad et al.'s studies, where the maximum isolates were from urine (68.7% and 60.4%, respectively).
In our study, the maximum number of Enterobacteriaceae isolates were resistant to cefotaxime (82%) followed by levofloxacin (63.5%) and Amoxclav (57.5%). Escherichia coli followed by Klebsiella pneumoniae were the predominant multidrug-resistant bacteria found to be similar to those reported in Moglad et al.'s study. In general, the increase in the resistance of isolated organisms to penicillin, fluoroquinolones, macrolides, and cephalosporins in this study might be due to the increase in the usage of these antibiotic classes in the hospital. We infer that a maximum number of isolates were resistant to cefotaxime (82%), which is in line with Alfola et al.'s and Iroha et al.'s studies, where isolates showed high resistance to cefotaxime.
Fluoroquinolones, such as ofloxacin, ciprofloxacin, levofloxacin, and others, have increasingly been used clinically because of their potent and broad antibacterial activity. In the present study, levofloxacin resistance was seen in 63.5% of isolates, which is found to be close to the finding of Mahamat et al., where it was reported as 55.34%.
The prevalence of ESBL-producing Enterobacteriaceae is found to be 29.5%, which is close to those reported in other studies carried out at different locations such as 33.2% in Nepal by Lohani et al., 38.4% in Jimma by Siraj and colleagues, 36% in Jimma by Mulualem and colleagues, 33.3% in Harar, and 25% in Adama. However, the incidence of ESBL producers such as in Bahir Dar, Ethiopia (57.6%), Burkina Faso (58.0%), Uganda (62.0%), Ghana (49.3%), and Karnataka, India (57.5%) were reported to be much higher as compared to our present results. The possible reason for the high magnitude of ESBL incidence could be due to the lack of antibiotic surveillance, antibiotic misuse, and weak infection control measures.
According to the CLSI, three phenotypic methods were used in the present study, which are the combined disk diffusion test, E-test, and HiCrome agar test. It was seen that all the 200 Enterobacteriaceae were screened positive, out of which 59 isolates were confirmed to be ESBL-positive. Our present finding is in accord with that of Shakya et al.'s study, where the screening test was positive for 168 isolates, out of which 36 were ESBL producers, and also with that of the observation by Yadav K et al. that reported 43 confirmed ESBL-positive isolates out of 69 suspected ESBL producers.
In the present study, all phenotypic methods were 100% in concordance with each other. Earlier, a discrepancy was seen in the detection of ESBL producers in different phenotypic methods. The E-test was found to be 100% sensitive comparable with Hassan et al.'s report that indicated 97% sensitivity. Interestingly, it was observed that the combined disk test using cefotaxime and ceftazidime disks with and without clavulanate was 100% sensitive, whereas in other earlier studies, it was seen that using cefotaxime drug alone showed the same result.
Specifically, out of 59 ESBL isolates, 42 (71.1%) were Escherichia coli, 13 (22%) were Klebsiella pneumoniae, and 4 (6.8%) were Proteus mirabilis. Escherichia coli was the predominant ESBL producer which is close to the finding of Al-Garni et al., where ESBL-producing E. coli (62.7%) were the most common, followed by K. pneumoniae (23.6%), P. mirabilis (10.8%), and others with lower rates (2.8%). Similar results were reported by Elhassan et al., who revealed that E. coli and K. pneumoniae were detected at high rates of 77.6%, and 22.4%, respectively. However, ESBL producers were reported to be different in an earlier study which reported that ESBL-E. coli (52.8%) were more prevalent, followed by ESBL-K. oxytoca (27.3%) and ESBL-K. pneumoniae (14.6%), whereas only one each of Providencia spp. (1/3) and C. koseri (1/3) was ESBL-positive. Our studies showed a sensitivity of 100% in detecting ESBL producers by ESBL HiCrome agar, as observed by Prabha et al. and is close to another report with a sensitivity of 94.4%.
| Conclusions|| |
ESBL-producing Enterobacteriaceae have disseminated worldwide, with very high prevalence in countries of low and middle income and a roughly 10% prevalence in the community and at hospital admission in high-income countries. For the judicious use of antibiotics, detection of ESBL producers is important. In this study, it is observed that for rapid detection of ESBL producers, combined disk, E-, and HiCrome agar tests are equally efficient. Restriction of extended-spectrum cephalosporin use is accompanied by switching empirical therapy for serious infections to other classes of antibacterials. The two most studied alternatives are imipenem and piperacillin/tazobactam.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ena J, Arjona F, Martínez-Peinado C, del mar Lopez-Perezagua M, Amador C. Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamaseproducing Escherichia coli. Urology 2006;68:1169-74.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 21st
Informational Supplement: Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2011. p. M100-S21.
Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum β lactamase producing Gram negative bacteria in a tertiary care hospital. Indian J Med Res 2002;115:153-7.
Hansotia JB, Agarwal V, Pathak AA, Saoji AM. Extended spectrum β lactamase mediate resistance to third generation cephalosporins in Klebsiella pneumoneae in Nagpur, central India. Indian J Med Res 1997;105:160-5.
Manchanda V, Singh NP, Goyal R, Kumar A, Thukral SS. Phenotypic characteristics of clinical isolates of Klebsiella pneumoniae and evaluation of available techniques for detection of extended spectrum beta lactamases. Indian J Med Res 2005;122:330-7.
Tankhiwale SS, Jalgaonkar SV, Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res 2004;120:553-6.
Jain A, Roy I, Gupta MK, Kumar M, Agarwal SK. Prevalence of extended spectrum β-lactamase producing Gram negative bacteria in septicaemic neonates in a tertiary care hospital. J Med Microbiol 2003;52:421-5.
Pitout JDLK. Extended-spectrum β-lactamase-producing Enterobacteriaceae: An emerging public-health concern. Lancet Infect Dis 2008;8:159-66.
Paterson DL. Resistance in Gram-Negative Bacteria: Enterobacteriaceae. Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Abayneh M, Tesfaw G, Abdissa A. Isolation of extended-spectrum β-lactamase- (ESBL-) producing Escherichia coli and Klebsiella pneumoniae from patients with community-onset urinary tract infections in Jimma University Specialized Hospital, Southwest Ethiopia. Can J Infect Dis Med Microbiol 2018;2018:4846159.
Bajpai T, Pandey M, Varma M, Bhatambare GS. Prevalence of TEM, SHV, and CTX-M Beta-lactamase genes in the urinary isolates of a tertiary care hospital Avicenna. J Med 2017;7:12-6.
Knothe H, Shah PDP, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to. Klebsiella pneumonia and Serratia Marscesence. Infection 1983;11:315-7.
Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000;21:455-8.
Sambrook J, Fritsch ER, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd
ed. Plainview, NY: Cold Spring Harbor Laboratory Press; 1989.
Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. Saudi J Biol Sci 2015;22:90-101.
Lohani B, Thapa M, Sharma L, Adhikari H, Sah AK, Khanal AB, et al
. Predominance of CTX-M Type Extended Spectrum-lactamase (ESBL) Producers Among Clinical Isolates of Enterobacteriaceae in a Tertiary Care Hospital, Kathmandu, Nepal. Open Microbiol J 2019;13:28-33.
Singh N, Pattnaik D, Neogi DK, Jena J, Mallick B. Prevalence of ESBL in Escherichia coli isolates among ICU patients in a tertiary care hospital. J Clin Diagn Res 2016;10:DC19-22.
Ejaz H, Ikram-ul-Haq, Zafar A, Mahmood S, Javed MM. Urinary tract infections caused by extended spectrum β-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumonia. Afr J Biotechnol 2011;10:16661-6.
Motayo BO, Akinduti PA, Adeyakinu FA, Okerentugba PO, Nwanze JC, Onoh CC, et al
. Antibiogram and plasmid profiling of carbapenemase and extended spectrum Beta-lactamase (ESBL) producing Escherichia coli and Klebsiella pneumoniae in Abeokuta, South western. Niger Afr Health Sci 2013;13:1091-7.
Moosavian M, Deiham B. Distribution of TEM, SHV and CTX-M Genes among ESBL-producing Enterobacteriaceae isolates in Iran. Afr J Microbiol Res 2012;6:5433-9.
Mabrouka B, Rahima T, Yousra O. Frequency and antibiotic resistance of Enterobacteriaceae isolated in community urinary tract infections at Tebessa Region. Biomed J Sci Tech 2019;12:9098-101.
El-sayed Marei Y, Mohamed AboulOla O, Zakaria El-Azab S, Mohammad Kishk R, Mohammad Fouad M. Detection of plasmid-mediated quinolone resistance determinants in ESBLs and non-ESBLs producing Enterobacteriaceae from urinary tract infections. Ann Clin Immunol Microbiol 2019;1:1008.
Chandel DS, Johnson JA, Chaudhry R, Sharma N, Shinkre N, Parida S, et al
. Extended-spectrum b-lactamase-producing Gram-negative bacteria causing neonatal sepsis in India in rural and urban settings. J Med Microbiol 2011;60:500-7.
Giriyapur RS, Nandihal NW, Krishna BV, Patil AB, Chandrasekhar MR. Comparison of disc diffusion methods for the detection of extended-spectrum beta lactamase-producing Enterobacteriaceae. J Lab Physicians 2011;3:33-6.
] [Full text]
Emmanuel U, Chris A, Jerry O, Stanley E, Grace U, Lilian O, et al
. Phenotypic characterization and comparative study on ESBL-producing. E. coli
of clinical origin. Int J Sci 2016;5:27-31.
Moglad EH. Antibiotics profile, prevalence of extended-spectrum Beta-lactamase (ESBL), and multidrug-resistant Enterobacteriaceae from different clinical samples in Khartoum State. Sudan Int J Microbiol 2020;2020:8898430.
Alfola MMHR, Kamel Z, El Din Nada MG, Rashed LA, El-Awady BA. Phenotypic and genotypic characterization of ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates from patient's urine. Int Arab J Antimicrob Agents 2016;6:1-8.
Iroha IR, Okoye E, Osigwe CA, Moses IB, Ejikeugwu CP, Nwakaeze AE. Isolation, phenotypic characterization and prevalence of ESBL-producing Escherichia Coli and Klebsiella species from orthopedic wounds in national orthopedic hospital Enugu (NOHE), South East Nigeria. J Pharma Care Health Sys 2017;4:1-5.
Mahamat OO, Lounnas M, Hide M, Dumont Y, Tidjani A, Kamougam K, et al
. High prevalence and characterization of extended-spectrum ß-lactamase producing Enterobacteriaceae in Chadian hospitals. BMC Infect Dis 2019;19:1-7.
Siraj SM, Ali S, Wondafrash B. Extended- spectrum β -lactamase production in Klebsiella pneumoniae and Escherichia coli at Jimma University specialized hospital, south-west, Ethiopia. Mol Microbiol Res 2015;5:1-9.
Mulualem Y, Kasa T, Mekonnen ZSS. Occurrence of extended spectrum beta-lactamases in multidrug resistant Escherichia coli isolated from a clinical setting in Jimma university specialized hospital, Jimma, Southwest Ethiopia. East Afr J Public Heal 2012;9:58-61.
Seid J, Asrat D. Occurrence of extended spectrum β-lactamase enzymes in clinical isolates of Klebsiella species from Harar region, eastern Ethiopia. Acta Trop 2005;95:143-8.
Mulisa G, Selassie LG, W T, Jarso G, Shiferew T, Zewdu A, et al
. Prevalence of extended Spectrum Beta-lactamase producing Enterobacteriaceae: A cross sectional study at Adama hospital, Adama, Ethiopia. J Emerg Infect Dis 2016;1:1-6.
Abera B, Kibret M, Mulu W. Extended-spectrum beta-lactamases and antibiogram in enterobacteriaceae from clinical and drinking water sources from Bahir Dar city, Ethiopia. PLoS One 2016;11:1-10.
Ouedraogo A-S, Sanou M, Kissou A, Sanou S, Solaré H, Kaboré F, et al
. High prevalence of extended-spectrum ß-lactamase producing enterobacteriaceae among clinical isolates in Burkina Faso. BMC Infect Dis 2016;16:326.
Kateregga JN, Kantume R, Atuhaire C, Lubowa MN, Ndukui JG. Phenotypic expression and prevalence of ESBL-producing Enterobacteriaceae in samples collected from patients in various wards of Mulago hospital. Uganda BMC Pharmacol Toxicol 2015;16:1-6.
Obeng-Nkrumah N, Twum-Danso K, Krogfelt KA, Newman MJ. High levels of extended-Spectrum Beta-lactamases in a major teaching Hospital in Ghana: The need for regular monitoring and evaluation of antibiotic resistance. Am J Trop Med Hyg 2013;89:960-4.
Rao SP, Rama PS, Gurushanthappa V, Manipura R, Srinivasan K. Extended spectrum Beta-lactamases producing Escherichia coli and Klebsiella pneumoniae: A multi-centric study across Karnataka. J Lab Physicians 2014;6:7-13.
] [Full text]
Shakya P, Shrestha D, Maharjan E, Sharma VK, Paudyal R. ESBL production among E. coli
and Klebsiella spp. causing urinary tract infection: A hospital based study. Open Microbiol J 2017;11:26-30.
Yadav K, Prakash S. Screening of ESBL producing multidrug resistant E. coli
from urinary tract infection suspected cases in Southern Terai of Nepal. J Infect Dis Diagn 2017;2:116.
Singh RM, Singh HL. Comparative evaluation of six phenotypic methods for detecting extended spectrum beta-lactamase-producing Enterobacteriaceae. J Infect Dev Ctries 2014;8:408-15.
Hassan H, Abdalhamid B. Molecular characterization of extended-spectrum beta-lactamase producing Enterobacteriaceae in a Saudi Arabian tertiary hospital. J Infect Dev Ctries 2014;8:282-8.
Garrec H, Drieux-Rouzet, Golmard JL, Jarlier V, Robert J. Comparison of nine phenotypic methods for detection of extended-spectrum β-lactamase production by Enterobacteriaceae. J Clin Microbiol 2011;49:1048-57.
Al-Garni SM, Ghonaim MM, Ahmed MMM, Al-Ghamdi AS, Ganai FA. Risk factors and molecular features of extended-spectrum beta-lactamase producing bacteria at southwest of Saudi Arabia. Saudi Med J 2018;39:1186-94.
Elhassan MM, Ozbazk HA, Hemeg HA, Ahmed AA. Dissemination of CTX-M extended-spectrum ß-lactamases (ESBLs) among Escherichia coli and Klebsiella pneumoniae in Al-Madenah Al-Monawwarah region, Saudi Arabia. Int J Clin Exp Med 2016;9:11051-7.
Prabha R, Easow JM, Swapna M. Phenotypic detection of extended spectrum Beta lactamase producing uropathogens using DDST, PCT, Chrom agar and E-test - A comparative study. Int J Curr Microbiol App Sci 2016;5:565-77.
Chetana GS, Yadhav KML. Rapid phenotypic detection of ESBL producing Enterobacteriaceae using ESBL hichrome agar and e test: A comparative study. Int J Curr Adv Res 2017;6:4665-8.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5]
[Table 1], [Table 2]